These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3189578)

  • 1. Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia.
    Ganey PE; Sprugel KH; White SM; Wagner JG; Roth RA
    Am J Physiol; 1988 Nov; 255(5 Pt 2):H1165-72. PubMed ID: 3189578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of thrombocytopenia on monocrotaline pyrrole-induced pulmonary hypertension.
    Hilliker KS; Bell TG; Lorimer D; Roth RA
    Am J Physiol; 1984 Jun; 246(6 Pt 2):H747-53. PubMed ID: 6742140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats.
    White SM; Wagner JG; Roth RA
    Toxicol Appl Pharmacol; 1989 Jun; 99(2):302-13. PubMed ID: 2734793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Hydroxytryptamine and thromboxane in platelets from rats treated with monocrotaline pyrrole.
    Ganey PE; Roth RA
    Toxicol Appl Pharmacol; 1987 Apr; 88(2):157-64. PubMed ID: 3564035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats.
    White SM; Roth RA
    Toxicol Appl Pharmacol; 1988 Dec; 96(3):465-75. PubMed ID: 2974653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
    Bruner LH; Bull RW; Roth RA
    Toxicol Appl Pharmacol; 1987 Oct; 91(1):1-12. PubMed ID: 3672514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement is not involved in monocrotaline pyrrole-induced pulmonary injury.
    Bruner LH; Johnson KJ; Till GO; Roth RA
    Am J Physiol; 1988 Feb; 254(2 Pt 2):H258-64. PubMed ID: 3344816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.
    Reindel JF; Ganey PE; Wagner JG; Slocombe RF; Roth RA
    Toxicol Appl Pharmacol; 1990 Nov; 106(2):179-200. PubMed ID: 2256110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE; Wagner JG; Roth RA
    Toxicol Appl Pharmacol; 1991 Jul; 109(3):421-31. PubMed ID: 1830177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboxane does not mediate pulmonary vascular response to monocrotaline pyrrole.
    Ganey PE; Roth RA
    Am J Physiol; 1987 Apr; 252(4 Pt 2):H743-8. PubMed ID: 2952022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
    Bruner LH; Johnson K; Carpenter LJ; Roth RA
    J Toxicol Environ Health; 1987; 21(1-2):205-17. PubMed ID: 3573071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocrotaline pyrrole-induced pulmonary hypertension in fawn-hooded rats with platelet storage pool deficiency: 5-hydroxytryptamine uptake by isolated, perfused lungs.
    Hilliker KS; Bell TG; Roth RA
    Thromb Haemost; 1983 Dec; 50(4):844-7. PubMed ID: 6665765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE; Sprugel KH; Hadley KB; Roth RA
    J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelets and the puzzles of pulmonary pyrrolizidine poisoning.
    Roth RA; Ganey PE
    Toxicol Appl Pharmacol; 1988 May; 93(3):463-71. PubMed ID: 3130680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole.
    Schultze AE; Emeis JJ; Roth RA
    Biochem Pharmacol; 1996 Jan; 51(2):187-91. PubMed ID: 8615888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Injury to the isolated, perfused lung by exposure in vitro to monocrotaline pyrrole.
    Hilliker KS; Roth RA
    Exp Lung Res; 1985; 8(4):201-12. PubMed ID: 4043006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early indications of monocrotaline pyrrole-induced lung injury in rats.
    Schultze AE; Wagner JG; White SM; Roth RA
    Toxicol Appl Pharmacol; 1991 Jun; 109(1):41-50. PubMed ID: 2038748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of dietary restriction and altered sodium intake on the cardiopulmonary toxicity of monocrotaline pyrrole.
    Ganey PE; Fink GD; Roth RA
    Toxicol Appl Pharmacol; 1985 Mar; 78(1):55-62. PubMed ID: 2930913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary hypertension and ECG changes from monocrotaline pyrrole in the rat.
    Bruner LH; Hilliker KS; Roth RA
    Am J Physiol; 1983 Aug; 245(2):H300-6. PubMed ID: 6224428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
    Hilliker KS; Roth RA
    Br J Pharmacol; 1984 Jun; 82(2):375-80. PubMed ID: 6234044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.